Literature DB >> 31254513

A longitudinal study of retinopathy in the PEX1-Gly844Asp mouse model for mild Zellweger Spectrum Disorder.

Catherine Argyriou1, Anna Polosa2, Bruno Cecyre3, Monica Hsieh4, Erminia Di Pietro5, Wei Cui6, Jean-François Bouchard7, Pierre Lachapelle8, Nancy Braverman9.   

Abstract

Zellweger Spectrum Disorder (ZSD) is an autosomal recessive disease caused by mutations in any one of 13 PEX genes whose protein products are required for peroxisome assembly. Retinopathy leading to blindness is one of the major untreatable handicaps faced by patients with ZSD but is not well characterized, and the requirement for peroxisomes in retinal health is unknown. To address this, we examined the progression of retinopathy from 2 to 32 weeks of age in our murine model for the common human PEX1-p.Gly843Asp allele (PEX1-p.Gly844Asp) using electrophysiology, histology, immunohistochemistry, electron microscopy, biochemistry, and visual function tests. We found that retinopathy in male and female PEX1-G844D mice was marked by an attenuated cone function and abnormal cone morphology early in life, with gradually decreasing rod function. Structural defects at the inner retina occurred later in the form of bipolar cell degradation (between 13 and 32 weeks). Inner segment disorganization and enlarged mitochondria were seen at 32 weeks, while other inner retinal cells appeared preserved. Visual acuity was diminished by 11 weeks of age, while signal transmission from the retina to the brain was relatively intact from 7 to 32 weeks of age. Molecular analyses showed that PEX1-G844D is a subfunctional but stable protein, contrary to human PEX1-G843D. Finally, C26:0 lysophosphatidylcholine was elevated in the PEX1-G844D retina, while phopshoethanolamine plasmalogen lipids were present at normal levels. These characterization studies identify therapeutic endpoints for future preclinical trials, including improving or preserving the electroretinogram response, improving visual acuity, and/or preventing loss of bipolar cells.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PEX1; Peroxisome disorders; Pex1 mouse model; Retinal degeneration; Zellweger spectrum disorder

Mesh:

Substances:

Year:  2019        PMID: 31254513     DOI: 10.1016/j.exer.2019.107713

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  5 in total

1.  Peroxisomal Multifunctional Protein 2 Deficiency Perturbs Lipid Homeostasis in the Retina and Causes Visual Dysfunction in Mice.

Authors:  Yannick Das; Daniëlle Swinkels; Sai Kocherlakota; Stefan Vinckier; Frédéric M Vaz; Eric Wever; Antoine H C van Kampen; Bokkyoo Jun; Khanh V Do; Lieve Moons; Nicolas G Bazan; Paul P Van Veldhoven; Myriam Baes
Journal:  Front Cell Dev Biol       Date:  2021-02-02

2.  Cell Type-Selective Loss of Peroxisomal β-Oxidation Impairs Bipolar Cell but Not Photoreceptor Survival in the Retina.

Authors:  Daniëlle Swinkels; Yannick Das; Sai Kocherlakota; Stefan Vinckier; Eric Wever; Antoine H C van Kampen; Frédéric M Vaz; Myriam Baes
Journal:  Cells       Date:  2022-01-04       Impact factor: 6.600

3.  A Pex7 Deficient Mouse Series Correlates Biochemical and Neurobehavioral Markers to Genotype Severity-Implications for the Disease Spectrum of Rhizomelic Chondrodysplasia Punctata Type 1.

Authors:  Wedad Fallatah; Wei Cui; Erminia Di Pietro; Grace T Carter; Brittany Pounder; Fabian Dorninger; Christian Pifl; Ann B Moser; Johannes Berger; Nancy E Braverman
Journal:  Front Cell Dev Biol       Date:  2022-07-11

Review 4.  Insights into the Structure and Function of the Pex1/Pex6 AAA-ATPase in Peroxisome Homeostasis.

Authors:  Ryan M Judy; Connor J Sheedy; Brooke M Gardner
Journal:  Cells       Date:  2022-06-29       Impact factor: 7.666

5.  The biochemical basis of mitochondrial dysfunction in Zellweger Spectrum Disorder.

Authors:  Esther Nuebel; Jeffrey T Morgan; Sarah Fogarty; Jacob M Winter; Sandra Lettlova; Jordan A Berg; Yu-Chan Chen; Chelsea U Kidwell; J Alan Maschek; Katie J Clowers; Catherine Argyriou; Lingxiao Chen; Ilka Wittig; James E Cox; Minna Roh-Johnson; Nancy Braverman; Joshua Bonkowsky; Steven P Gygi; Jared Rutter
Journal:  EMBO Rep       Date:  2021-08-05       Impact factor: 9.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.